Researchers at the Center for Genomic Regulation (CRG) reveal that metabolic enzymes known for their roles in energy ...
PARP1 is critical for repairing DNA single-strand breaks. First-generation PARP1/2 inhibitors have proven effective in the treatment of tumors with mutations in the essential homologous recombination ...
Metabolic enzymes, typically associated with energy production, are now discovered to also play essential roles in the nucleus, such as orchestrating cell division and DNA repair. This breakthrough, ...
Studies suggest the cell is more interconnected than previously thought, opening up "exciting possibilities for science and medicine." ...
AZ has been presenting preclinical data from AZD5305, its next-generation PARP1 inhibitor at the 2021 American Association for Cancer Research meeting, which the company thinks could be more ...
Merck gets exclusive rights to Hengrui’s PARP1 drug HRS-1167 outside China under the terms of the agreement, and also picks up an option for an ex-China license to SHR-A1904, an ADC directed at ...
So, as BRCA-deficient cells had previously been shown to be highly sensitive to the effects of inhibiting PARP1, Rottenberg and colleagues investigated the effects of the PARP1 inhibitor AZD2281 ...
Cleavage of Caspase 3, PARP1 and HSP90, as well as increased Annexin V positivity, suggests potent activation of apoptosis by this two-drug combination; increased levels of γ-H2AX, P-CHK1 (S317), ...
Stenoparib is an orally available, small-molecule, dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. At present, tankyrases are attracting significant attention as emerging therapeutic ...
For example, we found that cells lacking the common breast cancer tumour suppressors BRCA1 or BRCA2, which repair DNA through homologous recombination (HR), were remarkably sensitive to inhibition of ...
Phase 3 trial results showed that adding veliparib to temozolomide did not significantly improve overall or progression-free survival in newly diagnosed, MGMT-hypermethylated glioblastoma.